Avelumab and Valproic Acid for Virus-Associated Cancer

Unknown Phase 2 NCT03357757

Study Description

This clinical trial studies the effectiveness of Avelumab and Valproic acid in treating virus-associated cancer. Valproic acid can unmask a chronic viral infection, making the virus susceptible to attack by the immune system. When combined with Avelumab, an immune therapy, the body's immune defense against cancer is enhanced. Avelumab prevents the deactivation of a lymphocyte, re-energizing a person's immune system, leading to an attack on the cancer. Although Avelumab is an effective treatment for several cancers, its effectiveness in virus-associated cancer has not yet been studied. The combination of Valproic acid and Avelumab offers hopes for better results in treating cancer.

Study Details

Registry ID:
NCT03357757
Conditions:
Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix, p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva, p16 Positive Squamous Cell Carcinoma of the Penis, p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal, EBER Positive NPC, EBER Positive Hodgkins and Non-hodgkins Lymphona
Phase:
Phase 2
Target Enrollment:
39 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →